Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Orchard Therapeutics Plc ADR (NQ: ORTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Jan 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Orchard Therapeutics Plc ADR < Previous 1 2 Next > Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 May 07, 2024 Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List May 03, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy March 20, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. March 18, 2024 One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome February 05, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium February 02, 2024 Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy January 25, 2024 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases January 24, 2024 Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of... From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD December 11, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH November 30, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX November 28, 2023 From Kahn Swick & Foti, LLC Via Business Wire Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments November 13, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023 October 26, 2023 New clinical data beyond previously reported neurological and skeletal results demonstrate favorable outcomes for multiple disease manifestations not effectively addressed by the current standard of... From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023 October 24, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX October 06, 2023 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SP® Plus Corporation (Nasdaq - SP), Orchard Therapeutics plc (Nasdaq - ORTX), Summit Materials (NYSE - SUM) October 05, 2023 From Brodsky & Smith LLC Via GlobeNewswire Orchard Therapeutics PLC (NASDAQ: ORTX) Sets New 52-Week High in Thursday Session October 05, 2023 Via Investor Brand Network ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders October 05, 2023 From Halper Sadeh LLC Via Business Wire Kyowa Kirin to Acquire Orchard Therapeutics October 05, 2023 From Orchard Therapeutics (Europe) Limited; Kyowa Kirin Co., Ltd. Via GlobeNewswire Are Gene Therapy Stocks The Market's Next Big Winners? September 25, 2023 Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. Via MarketBeat Topics Artificial Intelligence Exposures Artificial Intelligence Orchard Therapeutics Announces Acceptance of Biologics License Application for OTL-200 in MLD and Receives Priority Review September 18, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Presentation of Data Comprising the Clinical Package for the OTL-200 BLA in MLD at the SSIEM Annual Symposium 2023 August 31, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Completes Submission of Biologics License Application for OTL-200 in MLD to U.S. FDA August 03, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel August 02, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Webcast Conference Call of Second Quarter 2023 Financial Results July 25, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Second Closing of Strategic Financing, Resulting in $34 Million of Additional Capital June 26, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics to Present at Stifel’s Genetic Medicines Day May 24, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Announces Positive Clinical and Preclinical Data in Programs Targeting Neurometabolic and CNS Disorders at ASGCT May 19, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Presents Data from Research Programs at ASGCT Demonstrating the Ability of HSC Gene Therapy to Address Larger Indications May 18, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire Orchard Therapeutics Reports First Quarter 2023 Financial Results and Announces Initiation of Rolling Submission for Biologics License Application of OTL-200 for Metachromatic Leukodystrophy to U.S. FDA May 15, 2023 From Orchard Therapeutics (Europe) Limited Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.